Using nanoparticles and peripheral clearance of amyloid-β in Alzheimer's disease model

- Posted in English by

This is another paper using light for targeting β-amyloid in Alzheimer disease with light in a very interesting strategy. It's known that it's possible to desegregate β-amyloid with near-infrared light. The scientists from China start from the premises that UV could be used to successfully target β-amyloid. Indeed UV does not penetrate past a few millimetres under skin, so there is no hope to reach the brain where resides much β-amyloid plaques.

Yet Mengmeng Ma and colleagues observed that there is no need to reach the brain, as removing β-amyloid in the blood stream makes it been removed from the brain. It's a phenomenon called "Peripheral clearance".

While β-amyloid deposition is located in the brain in Alzheimer disease, peripheral clearance of β-amyloid may possibly also lower brain levels. The kidney, the skin, the gastrointestinal tract, and the liver contribute to peripheral β-amyloid clearance. β-amyloid could be detected in urine of humans. Recent evidence suggested that hepatic clearance of β-amyloid is impaired in liver cirrhosis. There is some evidence that patients with chronic liver diseases have an increased risk for Alzheimer disease.

So it the idea that targeting β-amyloid on a peripheral artery is very attractive. But indeed the scientists from China could not use UV light to target any large artery because its very low penetrance. So they used a proxy: An engineered peptide which when illuminated with IR, restitues this energy as UV.

The authors say that was useful in a mice model of Alzheimer. Indeed this must be taken with a grain of salt as 1. desegregation of β-amyloid plaques seems to have no impact on Alzheimer disease in humans and 2. successful trials on mice models of neurodegenerative diseases are rarely successful on humans.

Nevertheless it's a very interesting article exploring new ideas.

Advertisement


This book retraces the main achievements of ALS research over the last 30 years, presents the drugs under clinical trial, as well as ongoing research on future treatments likely to be able stop the disease in a few years and to provide a complete cure in a decade or two.

Please, to help us continue to provide valuable information: